RT Journal Article
SR Electronic
T1 Pre-exposure Prophylaxis Uptake Concerns in the Democratic Republic of the Congo: Key Population and Healthcare Workers Perspectives
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.01.13.23284513
DO 10.1101/2023.01.13.23284513
A1 Shen, Yanhan
A1 Franks, Julie
A1 Reidy, William
A1 Olsen, Halli
A1 Wang, Chunhui
A1 Mushimbele, Nadine
A1 Mazala, Richted Tenda
A1 Tchissambou, Tania
A1 Malele, Faustin
A1 Kilundu, Apolinaire
A1 Bingham, Trista
A1 Djomand, Gaston
A1 Mukinda, Elie
A1 Ewetola, Raimi
A1 Abrams, Elaine J.
A1 Teasdale, Chloe A.
YR 2023
UL http://medrxiv.org/content/early/2023/01/17/2023.01.13.23284513.abstract
AB Key populations (KP) in the Democratic Republic of the Congo (DRC), including female sex workers (FSW), are disproportionally affected by HIV. Quantitative feedback surveys were conducted at seven health facilities in DRC with 70 KP clients enrolled in services to measure pre-exposure prophylaxis (PrEP) benefits and concerns. The surveys also assessed satisfaction with PrEP services and experiences of stigma at the health facilities. Thirty healthcare workers (HCW) were surveyed to measure attitudes, beliefs, and acceptability of providing services to KP. KP client survey participants were primarily female SW. KP clients reported that the primary concern about taking PrEP was fear of side effects. HCW concurred with clients that experienced and anticipated side effects were a primary PrEP uptake concern, along with costs of clinic visits.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the President’s Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC) under the terms of Cooperative Agreement Numbers U2GGH000994. JF, WR, HO, CW, NM, RTM, TT, FM, EAJ and CAT received funding for this work. TB, GD, EM and RE are employees of the CDC who, as the funder, contribute to study design and manuscript development but did not have access to participant information or study data.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:DRC Ministry of Public Health’s National Ethics Committee for Health Columbia University Irving Medical Center Institutional Review BoardI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe study includes data abstracted from medical charts, therefore, the study data belong to the government of DRC so cannot be made publicly available for download. The data can be shared when requested, inquiries should be sent to icap{at}columbia.edu